Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans.

Treanor JJ, Betts RF, Erb SM, Roth FK, Dolin R.

J Infect Dis. 1987 Aug;156(2):379-83. No abstract available.

PMID:
3598236
2.

Prevention from naturally acquired viral respiratory infection by interferon nasal spray.

Saito H, Takenaka H, Yoshida S, Tsubokawa T, Ogata A, Imanishi F, Imanishi J.

Rhinology. 1985 Dec;23(4):291-5.

PMID:
4081525
3.

Intranasal lymphoblastoid interferon ("Wellferon") prophylaxis against rhinovirus and influenza virus in volunteers.

Phillpotts RJ, Higgins PG, Willman JS, Tyrrell DA, Freestone DS, Shepherd WM.

J Interferon Res. 1984 Fall;4(4):535-41.

PMID:
6094684
4.

The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community.

Isomura S, Ichikawa T, Miyazu M, Naruse H, Shibata M, Imanishi J, Matsuo A, Kishida T, Karaki T.

Biken J. 1982 Sep;25(3):131-7.

PMID:
7165687
5.

An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2.

Phillpotts RJ, Scott GM, Higgins PG, Wallace J, Tyrrell DA, Gauci CL.

Antiviral Res. 1983 Aug;3(2):121-36.

PMID:
6312877
6.

Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2.

Hayden FG, Mills SE, Johns ME.

J Infect Dis. 1983 Nov;148(5):914-21.

PMID:
6355321
7.

Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers.

Samo TC, Greenberg SB, Couch RB, Quarles J, Johnson PE, Hook S, Harmon MW.

J Infect Dis. 1983 Sep;148(3):535-42.

PMID:
6619578
8.

Intranasal interferon-alpha 2 prophylaxis of natural respiratory virus infection.

Douglas RM, Albrecht JK, Miles HB, Moore BW, Read R, Worswick DA, Woodward AJ.

J Infect Dis. 1985 Apr;151(4):731-6. No abstract available.

PMID:
2982972
9.

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.

Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2006 Jul;78(7):954-63.

PMID:
16721854
10.

Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.

Bakke H, Samdal HH, Holst J, Oftung F, Haugen IL, Kristoffersen AC, Haugan A, Janakova L, Korsvold GE, Krogh G, Andersen EA, Djupesland P, Holand T, Rappuoli R, Haneberg B.

Scand J Immunol. 2006 Mar;63(3):223-31.

11.

Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness.

Hayden FG, Gwaltney JM Jr.

J Infect Dis. 1983 Sep;148(3):543-50.

PMID:
6311914
12.

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.

Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DA.

Antimicrob Agents Chemother. 1983 Nov;24(5):713-5.

13.

Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.

Bracci L, Canini I, Puzelli S, Sestili P, Venditti M, Spada M, Donatelli I, Belardelli F, Proietti E.

Vaccine. 2005 Apr 27;23(23):2994-3004.

PMID:
15811645
14.

Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.

Watanabe I, Ross TM, Tamura S, Ichinohe T, Ito S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.

Vaccine. 2003 Nov 7;21(31):4532-8.

PMID:
14575764
15.

Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection.

Calfee DP, Peng AW, Hussey EK, Lobo M, Hayden FG.

Antivir Ther. 1999;4(3):143-9.

PMID:
12731753
17.

Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose.

Samo TC, Greenberg SB, Palmer JM, Couch RB, Harmon MW, Johnson PE.

J Infect Dis. 1984 Aug;150(2):181-8.

PMID:
6381611
18.

Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus.

Bracci L, Canini I, Venditti M, Spada M, Puzelli S, Donatelli I, Belardelli F, Proietti E.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-56-7.

PMID:
16823927
19.

Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.

Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI.

Mucosal Immunol. 2008 May;1(3):208-18. doi: 10.1038/mi.2008.2. Epub 2008 Mar 5.

PMID:
19079180
20.

Immunoprophylactic strategies against respiratory influenza virus infection.

Saravolac EG, Sabuda D, Crist C, Blasetti K, Schnell G, Yang H, Kende M, Levy HB, Wong JP.

Vaccine. 2001 Mar 21;19(17-19):2227-32.

PMID:
11257338

Supplemental Content

Support Center